Vildagliptin
Eucreas, Galvus, Icandra, Jalra, Xiliarx, Zomarist (vildagliptin) is a small molecule pharmaceutical. Vildagliptin was first approved as Galvus on 2007-09-25. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD08: Metformin and vildagliptin
— A10BH: Dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering
— A10BH02: Vildagliptin
HCPCS
No data
Clinical
Clinical Trials
162 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | 5 | 71 | 46 | 5 | 130 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | 1 | 1 | 4 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | 1 | 2 | 1 | — | 4 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 2 | — | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | 2 | — | 2 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | 2 | — | 2 | |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | 1 | — | 1 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | 1 | — | 1 | 5 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | 1 | — | — | 2 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | 1 | — | — | 1 | |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | 1 | — | — | 1 |
| Retinal neovascularization | D015861 | H35.05 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 1 |
| Dyslipidemias | D050171 | HP_0003119 | — | 1 | — | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | — | 1 | — | — | — | 1 | ||
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Gestational diabetes | D016640 | HP_0009800 | O24.4 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | — | — | 2 | 2 | ||
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VILDAGLIPTIN |
| INN | vildagliptin |
| Description | Vildagliptin is an amino acid amide. |
| Classification | Small molecule |
| Drug class | dipeptidyl aminopeptidase-IV inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 274901-16-5 |
| RxCUI | 596554 |
| ChEMBL ID | CHEMBL142703 |
| ChEBI ID | — |
| PubChem CID | 6918537 |
| DrugBank | DB04876 |
| UNII ID | I6B4B2U96P (ChemIDplus, GSRS) |
Target
Agency Approved
DPP4
DPP4
Organism
Homo sapiens
Gene name
DPP4
Gene synonyms
ADCP2, CD26
NCBI Gene ID
Protein name
dipeptidyl peptidase 4
Protein synonyms
ADABP, ADCP-2, Adenosine deaminase complexing protein 2, CD26, Dipeptidyl peptidase IV, dipeptidylpeptidase 4, dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2), DPP IV, Gly-Pro naphthylamidase, Post-proline dipeptidyl aminopeptidase IV, T-cell activation antigen CD26, TP103, Xaa-Pro-dipeptidylaminopeptidase
Uniprot ID
Mouse ortholog
Dpp4 (13482)
dipeptidyl peptidase 4 (P28843)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Galvus - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,420 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,641 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more